BioPharma
Overcoming Treatment Challenges With Cell And Gene Therapies
Gene and cell therapies have the potential to revolutionize healthcare by reprogramming the immune system to treat diseases that are difficult to address with traditional...
BioPharma
Boosting Innovation And Value In UK Biopharma And Medtech
New recommendations from Imperial College London aim to boost competitiveness in the UK's biopharma and Medtech sectors. It assesses the value-added per capita in these...
BioPharma
Cell And Gene Therapy CDMO Services Market Is On The Rise
The global cell and gene therapy Contract Development and Manufacturing Organization (CDMO) services market, which was valued at USD 5,193.7 million in 2022, is expected...
Articles
What’s driving the growth of the biopharma sector across South East Asia?
Standfirst: The healthcare industry, particularly the life-science and biopharma sectors, across ASEAN is seeing a shift away from a reliance on overseas expertise and imported...
BioPharma
Lack of Experience Hinders CDMOs In Cell And Gene Therapy
CDMOs (contract development and manufacturing organizations) are facing challenges due to the increasing number of companies preparing to scale up their cell and gene therapy...
BioPharma
Cell and Gene Therapy CDMO Targets North American Growth with Major US Acquisition
uBriGene, a cell & gene therapy contract development and manufacturing organization (CDMO), is expanding into the US market with the acquisition of a state-of-the-art GMP...
BioPharma
Biopharma Spectrum To Be Driven By Automation In Next Decade
One of the reports concerning automation in the biopharmaceutical sector has gone on to show that the market is estimated to grow at a CAGR...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.